Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.

Isa Odidi

Amina Odidi

Intellipharmaceutics International Inc.

Jazz Pharmaceuticals is a global biopharmaceutical company dedicated to bringing life-changing medicines to people with limited or no options, enabling them to live their lives more fully.

Metric
Company Name	Intellipharmaceutics International Inc.	Jazz Pharmaceuticals
Symbol	IPCI
MSH ID	COM:INTELLIPHARMACEUTICS	COM:JAZZPHARMACEUTICALS
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Pharmaceuticals
Country	CA	US
Stage
Employee Count	11
Website	intellipharmaceutics.com	jazzpharmaceuticals.com
LinkedIn
Founders

Metric
Market Cap	1.87M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	65.73K
Revenue (LTM)
Revenue (NTM)
Gross Profit	65.73K
EBITDA	-2.64M
Operating Income	-2.85M
Net Income	-2.89M
EPS	-0.09
Diluted EPS	-0.09
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.03
Operating Profit Margin	-2.85
EBITDA Margin	-40.23
Net Profit Margin	-3.89
Return on Equity	0.31
Return on Assets	-2.25
Return on Capital Employed	0.20

IPCI

COM:INTELLIPHARMACEUTICS

Intellipharmaceutics International

Last Close

0.09

05/03 15:01

Market Cap

2.65M

Beta: -

Volume Today

16.90K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.63
P/B Ratio	-0.17
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	2.71
EV Multiple	-0.04

Metric
Days Sales Outstanding	108.17
Days Payables Outstanding	1.61K
Days Inventory Outstanding
Operating Cycle	108.17
Cash Conversion Cycle	-1.50K
Asset Turnover	0.58

Metric
Operating Cash Flow	-1.39M
Free Cash Flow	-1.39M
Cash Flow to Debt	0.05
Operating Cash Flow/Sales	0.13
Free Cash Flow Yield	0.05

Metric
Cash & Equivalents	83.72K
Accounts Receivable	-602
Inventory
Goodwill
Debt to Capitalization	-0.21
Debt to Assets	1.42
Current Ratio	0.06
Quick Ratio	0.05

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue	1.84
SG&A to Revenue